Ikarian Capital’s Jasper Therapeutics JSPR Stock Holding History

Ikarian Capital’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.1K	Hold	24,093	–	–	﹤0.01%	160
2025 Q4	$44.1K	Sell	24,093 -1,014	-4%	-$2.04K	﹤0.01%	166
2025 Q3	$59.8K	Hold	25,107	–	–	0.01%	164
2025 Q2	$139K	Hold	25,107	–	–	0.03%	120
2025 Q1	$108K	Sell	25,107 -30,000	-54%	-$200K	0.01%	150
2024 Q4	$1.18M	Sell	55,107 -68	-0.1%	-$1.42K	0.16%	102
2024 Q3	$1.04M	Sell	55,175 -50,000	-48%	-$996K	0.14%	96
2024 Q2	$2.39M	Hold	105,175	–	–	0.42%	51
2024 Q1	$3.09M	Buy	+105,175	New	+$1.87M	0.34%	70
2023 Q4	–	Sell	-112,509	Closed	-$788K	–	158
2023 Q3	$788K	Hold	112,509	–	–	0.09%	102
2023 Q2	$1.54M	Sell	112,509 -120	-0.1%	-$1.78K	0.25%	74
2023 Q1	$2.04M	Buy	+112,629	New	+$2.08M	0.46%	57

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Ikarian Capital's JSPR Position: Q1 2026 in Review

Ikarian Capital held its Jasper Therapeutics (JSPR) position steady in Q1 2026 at 24,093 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #160.

Ikarian Capital first reported a position in JSPR in Q1 2023 and has held it in 12 quarters since. The position peaked at $3.09M in Q1 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Ikarian Capital held 24,093 shares of Jasper Therapeutics worth $21.1K as of Q1 2026.
Ikarian Capital left its Jasper Therapeutics share count unchanged in Q1 2026.
Jasper Therapeutics made up ﹤0.01% of Ikarian Capital's portfolio in Q1 2026, its #160 holding.
Ikarian Capital first reported a position in Jasper Therapeutics in Q1 2023 and has held it in 12 quarters since.
Ikarian Capital's Jasper Therapeutics position peaked at $3.09M in Q1 2024.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.